Commercial development opportunities for pharma, biotech, and investors
Dean Tozer is Senior Vice President at Advanced BioHealing, Inc. (ABH). In this role he oversees marketing, corporate development, reimbursement, government affairs, product development, various regulatory functions and international expansion. Mr. Tozer joined ABH in M…more ›
Dr. Airriess has a Biomedical Ph.D. and extensive experience with emerging companies and the challenges that face them, including fund-raising and the FDA approval process. He has guided California Stem Cell's operations through startup into the pre-clinical develo…more ›
George Emont is a Managing Partner with Triathlon Medical Ventures and also a Managing Partner of the Kentucky Seed Capital Fund. Mr. Emont's 25 years of health care industry experience include 15 years in venture capital. Prior to joining Triathlon and KCSF, Mr. Em…more ›
Brock Reeve, a graduate of Yale and the Harvard Business School, is Executive Director of the Harvard Stem Cell Institute. In partnership with the Faculty Directors, he has overall responsibility for the operations and strategy of the institute whose mission is to use s…more ›
Ed Field is the Chief Operating Officer of Cytomedix, Inc. (OTC:CMXI), a US-based company that is developing and commercializing autologous regenerative biotherapies that facilitate the body’s natural healing processes for enhanced healing and tissue repair. Cytomedix’…more ›
Stem Cells USA & Regenerative Medicine Congress is the region's largest commercial stem cells conference
Most stem cell companies face two options - go bankrupt or find a partner with deep pockets. Despite there being hundreds of companies with promising technologies, most of them never pass Phase II trials due to lack of funding.
This year’s Stem Cells USA & Regenerative Medicine Congress will focus on strategies and business models to help you navigate this increasingly challenging marketplace, and to ensure your stem cell and regenerative medicine gets to market.
New to 2012 - this year's conference will take place alongside the World Cord Blood Congress. What does this mean for you? Double the networking and double the content.
Sponsors
6 reasons to attend
- Learn effective fund raising strategies
- Understand off-label applications
- Discover new developments in gene engineering
- Hear from Organogenesis, Athersys, Gamida Cell and more
- Learn recent advancements in iPS cells and bioaesthetics
- Get 2 events for the price of 1! Increase your exposure in the stem cells, regenerative medicine AND cord blood sectors
Don't just take our word for it
“Best conference and networking opportunity of 2011.”
Michael Voltruba, Director, International Development, PrimeCell/National Tissue Center
"The most productive stem cell [event] I have been to"
George Emont, MP, Triathlon Medical Ventures
Come to the Stem Cells USA &
Regenerative Medicine Congress to:
- Learn effective fund raising stratgies
- Understand off-label applications
- Discover new developments in gene engineering
- Hear from Organogenesis, Athersys, Gamida Cell and more
- Learn recent advancements in iPS cells and bioaesthetics
- Understand public and private cord blood banking business models and strategies
Who should attend the Stem Cells USA & Regenerative Medicine Congress:
- Pharma & biotech
- Government
- Academia
- Consultants
- CRO
- CMO
Contact us now to find out more about how your organization can get involved with this event!
The Stem Cells USA & Regenerative Medicine Congress focus:
- Getting funding to sustain clinical trials through phase 2
- Identifying mutually-beneficial partnership and collaborations
- Developing new business models for public and private cord blood banking
- Increasing successful cord blood transplantation
If you need to know the latest innovations in these areas you must attend.
